1. Home
  2. HR vs CYTK Comparison

HR vs CYTK Comparison

Compare HR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Healthcare Realty Trust Incorporated

HR

Healthcare Realty Trust Incorporated

HOLD

Current Price

$20.11

Market Cap

6.5B

Sector

Real Estate

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$77.07

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HR
CYTK
Founded
1992
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
7.6B
IPO Year
2006
2004

Fundamental Metrics

Financial Performance
Metric
HR
CYTK
Price
$20.11
$77.07
Analyst Decision
Hold
Strong Buy
Analyst Count
8
19
Target Price
$19.29
$89.26
AVG Volume (30 Days)
4.1M
2.5M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
5.20%
N/A
EPS Growth
60.77
N/A
EPS
N/A
N/A
Revenue
$1,180,546,000.00
$13,368,000.00
Revenue This Year
N/A
$7.37
Revenue Next Year
$3.14
$310.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.09
$29.31
52 Week High
$20.46
$80.20

Technical Indicators

Market Signals
Indicator
HR
CYTK
Relative Strength Index (RSI) 72.42 69.50
Support Level $17.44 $58.59
Resistance Level N/A N/A
Average True Range (ATR) 0.40 3.62
MACD 0.17 1.39
Stochastic Oscillator 87.24 84.90

Price Performance

Historical Comparison
HR
CYTK

About HR Healthcare Realty Trust Incorporated

Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: